Revolution’s KRAS drugs appear competitive in several lung cancer settings
Revolution Medicines revealed new data that suggest its closely watched KRAS-targeting cancer programs could be highly competitive with similar therapies already on the market. The biotech’s shares {$RVMD} closed 11% higher on Thursday after it ...
Revolution Medicines revealed new data that suggest its closely watched KRAS-targeting cancer programs could be highly competitive with similar therapies already on the market.
The biotech’s shares {$RVMD} closed 11% higher on Thursday after it ...
